A carregar...
Certolizumab pegol: a new biologic targeting rheumatoid arthritis
The past decade has been an exciting period for clinical research and patient care in rheumatoid arthritis. This is mostly due to targeted biologic agents that have changed the outcome of this disease. Certolizumab pegol (Cimzia®, UCB Inc., GA, USA), which targets TNF-α with a different mechanism of...
Na minha lista:
| Formato: | Artigo |
|---|---|
| Idioma: | en |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3971417/ https://ncbi.nlm.nih.gov/pubmed/20979550 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1586/eci.10.69 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|